These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. MEK inhibition is a promising therapeutic strategy for MLL-rearranged infant acute lymphoblastic leukemia patients carrying RAS mutations. Kerstjens M; Driessen EM; Willekes M; Pinhanços SS; Schneider P; Pieters R; Stam RW Oncotarget; 2017 Feb; 8(9):14835-14846. PubMed ID: 27588400 [TBL] [Abstract][Full Text] [Related]
4. Identification of co-expressed genes associated with MLL rearrangement in pediatric acute lymphoblastic leukemia. Zhang H; Liu B; Cheng J; Ma H; Li Z; Xi Y Biosci Rep; 2020 May; 40(5):. PubMed ID: 32347296 [TBL] [Abstract][Full Text] [Related]
6. Frequencies and prognostic impact of RAS mutations in MLL-rearranged acute lymphoblastic leukemia in infants. Driessen EM; van Roon EH; Spijkers-Hagelstein JA; Schneider P; de Lorenzo P; Valsecchi MG; Pieters R; Stam RW Haematologica; 2013 Jun; 98(6):937-44. PubMed ID: 23403319 [TBL] [Abstract][Full Text] [Related]
7. Association of high-level MCL-1 expression with in vitro and in vivo prednisone resistance in MLL-rearranged infant acute lymphoblastic leukemia. Stam RW; Den Boer ML; Schneider P; de Boer J; Hagelstein J; Valsecchi MG; de Lorenzo P; Sallan SE; Brady HJ; Armstrong SA; Pieters R Blood; 2010 Feb; 115(5):1018-25. PubMed ID: 19965632 [TBL] [Abstract][Full Text] [Related]
8. Extramedullary relapse of Aldoss I; Song JY Blood; 2018 May; 131(22):2507. PubMed ID: 29853461 [No Abstract] [Full Text] [Related]
9. Chemosensitivity is differentially regulated by the SDF-1/CXCR4 and SDF-1/CXCR7 axes in acute lymphoblastic leukemia with MLL gene rearrangements. Ando N; Furuichi Y; Kasai S; Tamai M; Harama D; Kagami K; Abe M; Goi K; Inukai T; Sugita K Leuk Res; 2018 Dec; 75():36-44. PubMed ID: 30453100 [TBL] [Abstract][Full Text] [Related]
10. Updates in Górecki M; Kozioł I; Kopystecka A; Budzyńska J; Zawitkowska J; Lejman M Biomedicines; 2023 Mar; 11(3):. PubMed ID: 36979800 [TBL] [Abstract][Full Text] [Related]
11. Complementary activities of DOT1L and Menin inhibitors in MLL-rearranged leukemia. Dafflon C; Craig VJ; Méreau H; Gräsel J; Schacher Engstler B; Hoffman G; Nigsch F; Gaulis S; Barys L; Ito M; Aguadé-Gorgorió J; Bornhauser B; Bourquin JP; Proske A; Stork-Fux C; Murakami M; Sellers WR; Hofmann F; Schwaller J; Tiedt R Leukemia; 2017 Jun; 31(6):1269-1277. PubMed ID: 27840424 [TBL] [Abstract][Full Text] [Related]